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ABSTRACT
Objectives To assess the benefits and harms of
reboxetineversusplaceboorselectiveserotoninreuptake
inhibitors (SSRIs) in the acute treatment of depression,
andtomeasuretheimpactofpotentialpublicationbiasin
trials of reboxetine.
Design Systematic review and meta-analysis including
unpublished data.
DatasourcesBibliographicdatabases(Medline,Embase,
PsycINFO, BIOSIS, and Cochrane Library), clinical trial
registries, trial results databases, and regulatory
authority websites up until February 2009, as well as
unpublished data from the manufacturer of reboxetine
(Pfizer, Berlin).
Eligibility criteria Double blind, randomised, controlled
trials of acute treatment (six weeks or more) with
reboxetine versus placebo or SSRIs in adults with major
depression.
Outcome measures Remission and response rates
(benefit outcomes), as well as rates of patients with at
least one adverse event and withdrawals owing to
adverse events (harm outcomes).
Data extraction and data synthesis The procedures for
data extraction and assessment of risk of bias were
alwaysconductedbyonepersonandcheckedbyanother.
If feasible, data were pooled by meta-analyses (random
effects model). Publication bias was measured by
comparing results of published and unpublished trials.
Results We analysed 13 acute treatment trials that were
placebo controlled, SSRI controlled, or both, which
included 4098 patients. Data on 74% (3033/4098) of
these patients were unpublished. In the reboxetine
versus placebo comparison, no significant differences in
remission rates were shown (odds ratio 1.17, 95%
confidence interval 0.91 to 1.51; P=0.216). Substantial
heterogeneity(I
2=67.3%)wasshowninthemeta-analysis
of the eight trials that investigated response rates for
reboxetine versus placebo. A sensitivity analysis that
excluded a small inpatient trial showed no significant
difference in response rates between patients receiving
reboxetine and those receiving placebo (OR 1.24, 95% CI
0.98 to 1.56; P=0.071; I
2=42.1%). Reboxetine was
inferior to SSRIs (fluoxetine, paroxetine, and citalopram)
for remission rates (OR 0.80, 95% CI 0.67 to 0.96;
P=0.015) and response rates (OR 0.80, 95% CI 0.67 to
0.95;P=0.01).Reboxetinewasinferiortoplaceboforboth
harm outcomes (P<0.001 for both), and to fluoxetine for
withdrawals owing to adverse events (OR 1.79, 95% CI
1.06to3.05;P=0.031).Publisheddataoverestimatedthe
benefit of reboxetine versus placebo by up to 115% and
reboxetine versus SSRIs by up to 23%, and also
underestimated harm.
Conclusions Reboxetine is, overall, an ineffective and
potentially harmful antidepressant. Published evidence
is affected by publication bias, underlining the urgent
need for mandatory publication of trial data.
INTRODUCTION
Reboxetine, the first selective norepinephrine (nora-
drenaline) reuptake inhibitor used in the treatment of
depression,
1 mainly acts by binding to the norepi-
nephrine transporter and blocking reuptake of extra-
cellularnorepinephrine.
2Thedrugis“indicatedforthe
acute treatment of depressive illness or major depres-
sion and for maintaining the clinical improvement in
patients initially responding to treatment.”
3 Reboxe-
tine has been approved for marketing in many Eur-
opean countries (for example, the United Kingdom
and Germany) since 1997. In the United States, how-
ever, the application for approval was ultimately
rejected after preliminary acceptance.
24
Compared with the overall amount of anti-
depressantsprescribed,reboxetine’sshareisrelatively
small. For example, of 974 million defined daily doses
of antidepressants prescribed in Germany in 2008,
reboxetine accounted for 6.7 million defined daily
doses.
5 The average cost of reboxetine per defined
dailydosewas€1.87(£1.54;$2.39)forEdronax(Pfizer,
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pared with €0.52 for selective serotonin reuptake inhibi-
tors (SSRIs), the most commonly prescribed anti-
depressants.
5
Although reboxetine has been claimed to show
superior efficacy to placebo and similar efficacy to
other antidepressants,
16-10 the clinical relevance of the
drug has been queried. A recent systematic review by
Cipriani et al
11 included a network meta-analysis of
active controlled trials and found that reboxetine was
not only significantly less effective than the other
newer antidepressants investigated, but was also the
drug with the highest dropout rates.
The German Institute for Quality and Efficiency in
Health Care (Institut für Qualität und Wirtschaftlich-
keit im Gesundheitswesen (IQWiG)) conducted a
health technology assessment of the short term and
long term benefits and harms of reboxetine, bupro-
pion,andmirtazapineinplacebocontrolledandactive
controlledtrialsofadultpatientswithmajordepressive
disorder. Both published and previously unpublished
data were considered. The full German language
report and an English summary are available on the
institute’s website.
1213 The responsibilities and metho-
dological approach of IQWiG are described in its
methods paper online.
14
This publication presents the main findings of the
reboxetine trials with the aim of assessing the benefits
(remission and response rates) and harms (rates of
patients with at least one adverse event and rates of
withdrawals owing to adverse events) of reboxetine
versus placebo or SSRIs in the acute treatment of
major depressive disorder. In addition, for the present
paper we assessed potential publication bias by com-
paringresultsfrompublishedandunpublishedtrialsof
reboxetine.
METHODS
We developed and followed a standardised protocol
for all steps of the review.
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Eligibility criteria
The health technology assessment report that formed
the basis of this publication included both published
and unpublished trials of reboxetine that had the fol-
lowing characteristics:
 Double blind, randomised controlled design
 Investigation of adult patients with major
depressive disorder as their primary diagnosis
according to the International Classification of
Diseases, the Diagnostic and Statistical Manual of
Mental Disorders, or the Research Diagnostic
Criteria
 Acute treatment (at least six weeks duration) or
long term treatment (at least six months (relapse)
or 12 months (recurrence)) for prevention of
relapse or recurrence
 Comparison of reboxetine with placebo or any
antidepressant (including St John’s wort);
treatment according to approval status in
Germany
 Evaluation of at least one prespecified patient
relevant outcome (in this context, the term
“patient relevant” refers to “how a patient feels,
functions, or survives”
16)
 Publication in English, German, or French (or
any other language if the trial was classified as
potentially relevant according to the English title
or abstract)
 Availability of a full text document (for example,
journal article or clinical study report).
Thispublicationislimitedtoacutetreatmenttrialsof
reboxetine versus placebo or SSRIs. The outcomes
presented are restricted to the most commonly
reported outcomes in depression trials. Benefit out-
comes were remission and response rates. Harm out-
comes were rates of patients with at least one adverse
event (any adverse event according to the definitions
used in the primary trials) and rates of withdrawals
owing to adverse events (any adverse event according
to the definitions used in the primary trials). Harms
were further described by the overall rates of patients
with serious adverse events (any serious adverse event
according to the definitions used in the primary trials).
According to the review protocol, response and
remission data were analysed on the basis of the defini-
tions and instruments used in the primary trials. All
trials applied the Hamilton depression rating scale and
10 trials additionally applied the Montgomery-Åsberg
depression rating scale. We primarily considered the
response and remission outcomes on the Hamilton
depression rating scale. In all trials, response was
defined as a reduction in the score on the Hamilton
depression rating scale of 50% or more from baseline
to end of study, and remission was defined as a reduc-
tion in the score on the Hamilton depression rating
scale to below an absolute threshold at end of study
(score ≤10 in all trials except in one trial where the
score threshold was ≤8).
Search strategy and study selection
We searched for relevant primary and secondary pub-
lications (systematic reviews and health technology
assessment reports) in Medline, Embase, PsycINFO,
BIOSIS, and the Cochrane Library published up
untilFebruary2009.Thefullsearchstrategy,including
the search terms used for the various databases, has
been described elsewhere.
12
We scrutinised the reference lists of the primary and
secondary publications retrieved to identify further
trials.Inaddition,clinicaltrialregistriesandtrialresults
databases available on the internet were screened, as
were the websites of the European Medicines Agency
and the US Food and Drug Administration.
In order to obtain the most complete dataset possi-
ble,weaskedthemanufacturerofreboxetine(Pfizer)to
supply unpublished trials and additional unpublished
datafrompublishedtrials.Asaprerequisitefortheuse
of unpublished data, IQWiG asked the manufacturer
to sign an agreement requiring: (1) submission of a list
RESEARCH
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investigating reboxetine; (2) submission of documents
(generallytheclinicalstudyreports)compliantwiththe
CONSORT criteria for all relevant trials selected by
IQWiG; and (3) permission for publication of all pre-
viouslyunpublishedrelevantdata.Thisprocedurewas
required to avoid bias through selective provision of
data. Finally, people and parties who had submitted
comments on the preliminary version of the health
technology assessment report at the public hearing in
July 2009 were asked to provide any additional rele-
vant trials.
Two reviewers independently screened titles and
abstracts of the retrieved citations to identify poten-
tially eligible primary and secondary publications. In
a first broad screening step, citations were excluded if
clearly irrelevant; that is, if a primary publication was
not a clinical trial in humans with depression, or if a
secondary publication of eligible trials was not a sys-
tematic review. In a second screening step, the full set
of eligibility criteria was applied. Potentially relevant
articles were then screened as full texts. Disagreement
was resolved by consensus.
Data extraction and assessment of risk of bias
The individual steps of the data extraction and assess-
mentofriskofbiaswerealwaysconductedbyoneper-
son and checked by another. Details of the trials were
extracted using standardised tables. Information and
data from publications were supplemented by clinical
study reports provided by the manufacturer. We
always extracted data from the intention to treat popu-
lations. Clinical study reports were always considered
theprimarysourceininstancesofconflictwiththepub-
lication. Disagreement was resolved by consensus.
Informationwasextractedfromeachincludedtrialon:
 Study characteristics, including citation, study
design, setting (inpatient or outpatient), inclusion
and exclusion criteria, length of follow-up,
sample size, location, number of centres, and
year of completion
 Characteristics of the study participants,
including age, gender, and disease severity at
baseline
 Characteristics of the test and control
interventions, including dose
 Outcomes and type of outcome measures
(outcomes as presented above; measurement
tools as used in the individual trials)
 Risk of bias items.
Theriskofbiasatthestudylevelwasassessedonthe
basis of the adequacy of the following criteria: rando-
misation; allocation concealment; blinding of patients
and investigators; and complete and non-selective
results reporting. The risk of bias at the outcome level
was assessed on the basis of the adequacy of: applica-
tion of the intention to treat principle; blinding of the
outcome assessor; statistical evaluation; and complete
and non-selective results reporting. Trials and out-
comes were categorised into those with a low risk of
bias and those with a high risk.
Data analysis
Iffeasibleandmeaningful,data werepooledbymeans
of meta-analyses. Effect measures were reported as
odds ratios (ORs) and 95% confidence intervals (CIs)
for binary data. A random effects model was used to
calculate a pooled effect estimate. Statistical signifi-
cancewasassumedforP<0.05.Heterogeneityofeffect
sizes was assessed by using the I
2 statistic; pooled esti-
mates were not calculated if substantial heterogeneity
was observed (I
2>50%). If heterogeneity with I
2>50%
was shown, sensitivity analyses were conducted, when
appropriate,toassesspossiblesourcesofheterogeneity
across the trials included. The review protocol prespe-
cified potential effect modifiers, including gender and
trial setting (inpatient or outpatient). These factors
were investigated by means of random effects meta-
regression analyses based on aggregate study data.
17
Records identified through database search (n=4347)
Duplicates (n=1751)
Excluded primary publications of patients with
  depression (n=700):
    Inappropriate indication (n=65)
    Inappropriate intervention (n=172)
    Inappropriate control intervention (n=215)
    Not double blind randomised controlled trial (n=165):
      No randomised controlled trial (n=117)
      Not double blind (n=48)
    Duration too short (n=36)
    No relevant end points (n=2)
    Inappropriate language of publication (n=11)
    No full publication (n=30)
    No re-randomisation (n=4)
Excluded (n=1883):
  Not relevant (n=1822)
  Relevant systematic reviews and health technology
    assessment reports (n=45)
  Publications not available (n=16)
Incompletely published studies (n=3)
Studies provided by manufacturer (n=10):
  Unpublished (n=7)
  Incompletely published (n=3)
Records screened (after duplicates removed) (n=2596)
Primary publications in patients with depression (n=713)
Published and unpublished studies (n=17)
Studies identified from bibliographic databases
(n=10 studies, 13 publications)
Excluded (n=4):
  Relapse prevention trials (n=2)
  Tricyclic antidepressant controlled trials (n=2)
Placebo controlled and selective serotonin reuptake inhibitor
  controlled studies (n=13):
    Included in qualitative synthesis (n=13)
    Included in quantitative synthesis (n=12)*
Fig 1 | Flowchart of study selection. *Excluding long term acute
treatment trial
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lished, unpublished, and overall dataset were com-
pared. In addition, the differences in effect sizes
betweenpublishedandunpublisheddata,andbetween
publishedandoveralldata,wereexpressedastheratio
of odds ratios (ROR). The magnitude of the overesti-
mation or underestimation of effect sizes in published
versus overall data (publication bias) was expressed as
percentage changes.
Meta-analyses were performed using SAS version
9.1.3. If meta-analyses were not possible, the results
of the individual trials were assessed.
RESULTS
Study selection
The process of study selection is presented in figure 1.
The search in bibliographic databases yielded 2596
citations, of which 713 were classified as potentially
relevant and subjected to strict eligibility assessment.
A total of 13 citations (10 trials) met the inclusion cri-
teria; however, two of these 13 citations were publica-
tionsonsubgroupsofotherwiseunpublishedtrials,
1819
and one wasthe only available publication on the total
population being studied but did not report the main
outcomes.
20 In the assessment of publication bias, we
considered these three trials to be “unpublished.” No
trialswereidentifiedinclinicaltrialortrialresultsregis-
tries or in the European Medicines Agency or FDA
websites.
Theretrievalofpreviouslyunpublishedtrialswasham-
pered by the fact that during preparation of the prelimin-
ary health technology assessment report, the
manufacturer of reboxetine did not provide a complete
listofunpublishedtrialsasrequestedbyIQWiG.
2122Sec-
ondary publications clearly indicated that further poten-
tially relevant unpublished trials existed.
68 As the
preliminary report showed that reboxetine had been
tested in at least 16 trials including about 4600 patients,
but data on almost two thirds of these patients were not
Table 1 |Trial publication details
Trial
Year of
completion Primary publication available?
Clinicalstudyreport
available?*
014 Before 1996 Refs 42-44 Ref 45†
015 1992 None, only a pooled analysis (ref 6) Ref 46
016 1993 Ref 47 Ref 48
032 2001 None Ref 49
043 2001 Ref 50 Ref 51
045 1999 None Ref 52
046 2000 None Ref 53
047 2000 Ref 19, although the data for the full study
population were not reported
Ref 54
049 1998 None Ref 55
050 1999 Ref20,althoughonlydataonsexualdysfunction
and other adverse events were reported
Ref 56
052 2000 Ref 18, although the data for the full study
population were not reported
Ref 57
091 1990 Refs 58 and 59 Ref 60
Berlanga and Flores-
Ramos 2006
2003 Ref 61 No
*As a matter of principle, the German Institute for Quality and Efficiency in Health Care requests documents
compliant with the CONSORT criteria from manufacturers on all relevant trials selected. If cooperative,
manufacturers usually provide the full clinical study report; that is, a written description of the study that
follows the guidelines of the International Conference on Harmonisation.
62
†Only addendum.
Remission
  014
  015
  046
  047
  050
  045
  049
Total
Total heterogeneity: I2=49.0%, P=0.068; total effect: P=0.216
Response
  014
  015
  046
  047
  050
  045
  049
Total
Total heterogeneity: I2=42.1%, P=0.110; total effect: P=0.071
  091
2.51 (1.49 to 4.25)
1.32 (0.77 to 2.27)
1.09 (0.77 to 1.55)
1.15 (0.80 to 1.66)
0.82 (0.51 to 1.34)
0.83 (0.45 to 1.54)
1.07 (0.58 to 1.98)
1.17 (0.91 to 1.51)
2.47 (1.49 to 4.11)
1.32 (0.78 to 2.25)
1.09 (0.76 to 1.55)
1.23 (0.86 to 1.77)
0.91 (0.57 to 1.45)
0.92 (0.50 to 1.67)
1.29 (0.74 to 2.27)
1.24 (0.98 to 1.56)
11.43 (3.10 to 42.12)
13.2
12.7
19.1
18.7
14.4
10.8
11.0
100.00
13.1
12.3
19.3
19.0
14.4
10.5
11.4
100.00
0.20 0.33 0.50 1 2 3 5
Trial
Control better Reboxetine better
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
60/126
47/110
132/252
109/238
48/144
30/88
29/106
455/1064
70/126
65/110
144/252
120/238
60/144
38/88
42/106
539/1064
20/27
Reboxetine
(n/N)
34/128
40/111
124/247
101/239
54/143
33/86
27/104
413/1058
43/128
58/111
136/247
108/239
63/143
39/86
35/104
482/1058
5/25
Placebo
(n/N)
Fig 2 | Forest plot showing meta-analyses of remission and response rates for trials that compared reboxetine with placebo.
Empty boxes show published studies and filled boxes show unpublished studies. Study 091 is not included in the pooled
analysis of response of reboxetine versus placebo because of high heterogeneity (see text for details). CI, confidence interval;
n, number of patients with event; N, number of patients in treatment group
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ingful assessment of reboxetine was possible.
2122
After the publication of the preliminary report, the
manufacturerdecidedtocooperateandprovidedmost
of the missing data (one venlafaxine controlled trial
23
was not available as a full publication). Thus, an addi-
tional10previouslyunpublishedorincompletelypub-
lished reboxetine trials were considered in the final
health technology assessment report.
12 Two trials
with tricyclic antidepressants as active controls and
two relapse prevention trials were excluded from the
present analysis.
Of the remaining 13 eligible acute treatment trials,
three were placebo controlled, five were active con-
trolled, and five had both placebo and active
controlled arms (one of which had a tricyclic anti-
depressant arm that was not considered). A total of
4098 patients were analysed: 2256 in the reboxetine
versus placebo comparisons and 2641 in the reboxe-
tine versus SSRI comparisons.
Study characteristics
Thecharacteristicsofthepoolof13acutetreatmenttrials
that were placebo controlled, SSRI controlled, or both
arepresentedintables 1and2.Alltrialsweresponsored
by predecessors of Pfizer (Pharmacia, and Pharmacia &
Upjohn), except for Berlanga and Flores-Ramos 2006
(sponsored by Lundbeck), and included adult patients
with major depressive disorder according to the third
edition, revised or the fourth edition of the Diagnostic
Table 2 |Trial characteristics and baseline demographics
Trial Treatments
Dose
(mg/d)
Proportion
of maximum
approved
daily dose
(%)
Number of
patients
randomised
Duration
of active
medication
(weeks)
Number of
centres
(locations)* Setting
Baseline demographics
Total
disconti-
nuation
rate (%)†
Age
(mean
(SD))
Proportion
female (%)
Hamilton
depression rating
scale 21 (mean
(SD))
014
Reboxetine 8-10 67-83 126
8
33 (Europe, South
America)
Inpatient
and
outpatient
40 (12) 67 26.8 (3.4) 30
Fluoxetine 20-40 25-50 127 40 (12) 65 26.9 (3.6) 24
Placebo —— 128 44 (12) 54 27.4 (3.6) 41
015
Reboxetine 8-10 67-83 112
6
34(NorthAmerica,
Europe, Australia)
Inpatient
and
outpatient
46 (13) 63 27.5 (5.1) 21
Imipramine 150-200 Inpatient:
50-67
Outpatient:
100-133
115 44 (11) 67 26.9 (4.7) 33
Placebo —— 112 43 (12) 48 27.1 (5.3) 23
016
Reboxetine 8-10 67-83 79
8
16 (Europe, South
America,
Australia)
Inpatient
and
outpatient
44 (13) 72 28.6 (5.3) 25
Fluoxetine 20-40 25-50 89 44 (12) 72 27.4 (4.1) 23
032
Reboxetine 8-10 67-83 43
8 5 (Asia)
Inpatient
and
outpatient
41 (15) 63 27.2 (5.4) 35
Fluoxetine 20-40 25-50 42 36 (13) 62 28.3 (5.3) 31
043
Reboxetine 8-10 67-83 183
24 23 (Europe) Outpatient
43 (13) 69 27.4 (3.5) 50
Citalopram 20-40 33-67 176 42 (12) 60 27.4 (3.9) 31
045
Reboxetine 8 67 89
64 8 ( E u r o p e , A s i a )
Inpatient
and
outpatient
42 (11) 63 26.4 (2.6) 30
Placebo —— 87 41 (11) 70 26.4 (2.6) 23
046
Reboxetine 8-10 67-83 265
89 4 ( N o r t h A m e r i c a ) N / A
40 (11) 71 23.0 (5.5) 25
Paroxetine 20-40 40-80 265 40 (12) 69 22.8 (5.4) 22
Placebo —— 257 39 (12) 70 23.0 (5.2) 16
047
Reboxetine 8-10 67-83 258
86 8 ( N o r t h A m e r i c a ) N / A
39 (12) 74 24.2 (4.9) 27
Paroxetine 20-40 40-80 262 40 (11) 72 23.9 (5.4) 28
Placebo —— 254 37 (11) 82 23.7 (4.8) 23
049
Reboxetine 8-10 67-83 107
6 9 (North America) Outpatient
40 (12) 55 25.1 (2.6) 35
Placebo —— 105 40 (11) 58 25.3 (3.0) 22
050
Reboxetine 8-10 67-83 150
8 24(NorthAmerica) Outpatient
40 (11) 63 25.6 (3.4) 42
Fluoxetine 20-40 25-50 150 41 (11) 66 26.0 (3.3) 31
Placebo 150 40 (11) 60 25.5 (3.3) 40
052
Reboxetine 8-10 67-83 159
84 1 ( E u r o p e ) N / A
42 (12) 63 24.2 (3.6) 33
Paroxetine 20-40 40-80 166 45 (11) 62 24.1 (3.4) 20
091
Reboxetine 10 83 28
6
3 (North America,
South America)
Inpatient
42 (N/A) 46 35.7 (N/A) 14
Placebo —— 28 40 (N/A) 50 35.1 (N/A) 57
Berlanga and
Flores-Ramos
2006
Reboxetine 4-8 33-67 46
8 1(CentralAmerica) Outpatient
N/A N/A N/A 10
Citalopram 20-40 33-67 55 N/A N/A N/A 25
*Details on individual countries are provided in web table A.
†To comply with the intention to treat principle, missing data from discontinued patients were imputed by using the last observation carried forward method.
N/A, not available.
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etine controlled trials and in one citalopram controlled
trial, the SSRIs were potentially underdosed compared
with reboxetine (according to doses standardised on the
basis of the maximum approved dose; see table 2). The
trials were well balanced between treatment arms with
respect to patient baseline characteristics.
There were no major differences between trials in
terms of dosage and mean patient age. However,
there were differences in setting (inpatient, outpatient,
or both) and baseline severity of depression as mea-
sured by the Hamilton depression rating scale. For
more details on trial characteristics see web table A.
Risk of bias
The overall methodological quality of the trials was
good (table 3). At the trial level, the risk of bias was
low in all but one study, which had a high risk of bias
at the trial level owing to unclear allocation conceal-
ment and blinding. At the outcome level, the risk of
bias was low for all four benefit and harm outcomes in
nine out of the 13 trials. Three trials had a high risk of
bias at the outcome level owing to an inadequate inten-
tion to treat analysis. Analyses excluding the outcomes
athighriskofbiasdidnotaltertheconclusions(datanot
shown). As no clear dose-response relationship has
been shown for fluoxetine and citalopram,
2425 the
potential underdosing of these agents in five trials did
not affect the risk of bias.
Owing to the availability of a comprehensive set of
the relevant data on reboxetine versus placebo and
SSRIs, the risk of publication bias on the results of the
final analysis was minor.
Effects of interventions
In thistext, the terms“superior” and“inferior”refer to
statistically significant differences between treatment
groups (P<0.05).
Meta-analyses of remission and response rates
The Hamilton depression rating scale was used in
the meta-analyses of remission and response rates.
Nostatisticallysignificantdifferencebetweenrebox-
etine and placebo was noted in the meta-analysis of
remission rates (OR 1.17, 95% CI 0.91 to 1.51;
P=0.216; fig 2).
Substantial heterogeneity (I
2=67.3%; p=0.003) was
shown in the meta-analysis of response rates including
all eight trials that compared reboxetine with placebo,
and consequently no point estimate was calculated.
The only known inpatient trial—trial 091 (n=52),
which had an OR of 11.43 (95% CI 3.10 to 42.12)—
was obviously a statistical outlier (figure 2).
Inthesensitivityanalysisusingmeta-regressionana-
lysis, setting had an effect on the outcome response.
Patients who received reboxetine in an inpatient set-
ting were more likely to show a good response com-
pared with placebo than were patients who received
reboxetine in an outpatient setting (P=0.001 inpatients
v outpatients; trials 091 v 049 and 050). In a second
scenario, the proportion of inpatients was used as the
independentvariable.Thisanalysisalsoincludedtrials
014and015,forwhichtheproportionofinpatientswas
available from Montgomery et al 2003.
7 This scenario
confirmed the influence of setting (P<0.001). The
meta-analysis of response rates in the outpatient only
trials (049 and 050) showed no statistically significant
difference between reboxetine and placebo (OR 1.05,
95% CI 0.73 to 1.50; P=0.796 I
2=0%). These findings
indicate that patient setting was the most probable
effect modifier. After exclusion of trial 091, the
meta-analysis of response rates in the seven remaining
trials showed no statistically significant difference
between reboxetine and placebo (OR 1.24, 95% CI
0.98 to 1.56, P=0.071, I
2=42.1%; figure 2).
Reboxetine was inferior to SSRIs in the meta-analy-
sis of remission rates (OR 0.80, 95% CI 0.67 to 0.96;
P=0.015; fig 3). A similar, although non-significant,
trend in remission rates was shown when reboxetine
was compared with the individual SSRIs (fluoxetine,
paroxetine, and citalopram). However, if remission
ratesaccordingtotheMontgomery-Åsbergdepression
ratingscaleratherthantheHamiltondepressionrating
scalewereanalysedfromtrialsusingthisinstrumentas
the primary scale (trials 046 and 047), reboxetine was
inferior to paroxetine (OR 0.72, 95% CI 0.56 to 0.93).
Inthelongtermacutetreatmenttrial(trial043),rebox-
etinewasinferiortocitalopram(OR0.51,95%CI0.32
to 0.83). However, the intention to treat principle was
violated in this trial, so a worst case analysis was con-
ducted in which the difference in remission rate com-
pared with citalopram was no longer statistically
significant.
Reboxetine was also inferior to SSRIs in the meta-
analysis of response rates (OR 0.80, 95% CI 0.67 to
0.95; P=0.010). A similar trend was shown when
reboxetine was compared with the individual SSRIs,
where the trend reached statistical significance in the
comparison of reboxetine and paroxetine (OR 0.79,
Table 3 |Risk of bias
Trial
Risk of bias:
trial level
Risk of bias: outcome level
Remission Response
Adverse
events
Withdrawals owing
to adverse events
014 High* High† High† High† High†
015 Low Low Low Low Low
016 Low Low Low Low Low
032 Low High‡ High‡ Low Low
043 Low High‡ High‡ Low Low
045 Low Low Low Low Low
046 Low Low Low Low Low
047 Low Low Low Low Low
049 Low Low Low Low Low
050 Low Low Low Low Low
052 Low Low Low Low Low
091 Low Low Low Low Low
Berlanga and
Flores-Ramos
2006
Low High‡ High‡ No data No data
*High because of unclear randomisation, allocation concealment, and blinding.
†High because of high risk of bias at trial level.
‡High because of violation of the intention to treat principle.
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page 6 of 14 BMJ | ONLINE FIRST | bmj.com95% CI 0.64 to 0.99; P=0.04). In the long term acute
treatment trial, no statistically significant difference
was shown between reboxetine and citalopram (OR
0.60, 95% CI 0.35 to 1.03).
Theoverallfindingswerealsoreflectedinthesubset
of trials that were both placebo controlled and SSRI
controlled (n=4), which are suited to demonstrating
assay sensitivity. The SSRIs were superior to placebo
and reboxetine in this analysis, but no statistically sig-
nificant difference was shown between reboxetine and
placebo (see web figure A).
Meta-analyses of adverse events and withdrawals owing to
adverse events
Reboxetine wasinferior toplacebo (thatis, it wasasso-
ciated with higher event rates) in the meta-analyses of
the ratesofpatientswithat leastoneadverseeventand
in the meta-analysis of the rates of withdrawals owing
to adverse events (OR 2.14, 95% CI 1.59 to 2.88;
P<0.001 and OR 2.21, 95% CI 1.45 to 3.37; P<0.001,
respectively; fig 4).
The rates of patients with at least one adverse event
did not differ significantly between patients treated
with reboxetine and those who received an SSRI (OR
1.06, 95% CI 0.82 to 1.36; P=0.667; fig 5). The same
finding was seen for patients on reboxetine versus
thosetreatedwithindividualSSRIs.Ameta-regression
analysis showed a gender effect in the comparison of
reboxetinewithfluoxetine(P=0.022fortheinteraction
test):inmenreboxetinewasinferiortofluoxetineinthe
meta-analysis of patients with at least one adverse
event (OR 2.76, 95% CI 1.28 to 5.93), whereas no sig-
nificant difference was shown in women (OR 0.90,
95% CI 0.51 to 1.59). In the long term acute treatment
trial, reboxetine was inferior to citalopram (OR 1.57,
95% CI 1.03 to 2.38).
0.20 0.33 0.50 1 23 5
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Control better Reboxetine better
Odds ratio
(95% CI)
Odds ratio
(95% CI)
Weight
(%)
Reboxetine
(n/N)
Remission
Fluoxetine
  014
  016
  050
  032
Fluoxetine subtotal
Subtotal heterogeneity: I2=16.1%, P=0.311; subtotal effect: P=0.306
Paroxetine
  046
  047
  052
Paroxetine subtotal
Subtotal heterogeneity: I2=40.8%, P=0.184; subtotal effect: P=0.104
Citalopram
  Berlanga and Flores-Ramos 2006
Total
Total heterogeneity: I2=4.6%, P=0.395; total effect: P=0.015
Response
Fluoxetine
  014
  016
  050
  032
Fluoxetine subtotal
Subtotal heterogeneity: I2=9.6%, P=0.345; subtotal effect: P=0.212
Paroxetine
  046
  047
  052
Paroxetine subtotal
Subtotal heterogeneity: I2=0.0%, P=0.644; subtotal effect: P=0.040
Citalopram
  Berlanga and Flores-Ramos 2006
Total
Total heterogeneity: I2=0.0%, P=0.737; total effect: P=0.010
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0.59 (0.37 to 0.95)
0.88 (0.35 to 2.18)
0.85 (0.62 to 1.16)
0.66 (0.46 to 0.94)
1.03 (0.72 to 1.48)
0.70 (0.45 to 1.09)
0.79 (0.59 to 1.05)
0.64 (0.26 to 1.57)
0.80 (0.67 to 0.96)
0.95 (0.58 to 1.57)
1.15 (0.58 to 2.29)
0.59 (0.37 to 0.94)
0.91 (0.37 to 2.24)
0.82 (0.60 to 1.12)
0.74 (0.52 to 1.07)
0.91 (0.63 to 1.30)
0.71 (0.45 to 1.11)
0.79 (0.64 to 0.99)
0.67 (0.26 to 1.70)
0.80 (0.67 to 0.95)
12.2
7.6
13.1
3.7
22.3
22.2
15.1
3.8
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6.3
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3.7
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51/79
48/144
14/38
173/387
132/252
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69/152
310/642
12/42
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59/79
60/144
21/38
210/387
144/252
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28/42
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57/127
58/89
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17/44
564/ 1093
72/127
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23/40
238/400
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128/242
100/164
384/649
33/44
655/1093
Selective serotonin
reuptake inhibitor (n/N)
Fig 3 | Forest plot showing meta-analyses of remission and response rates for trials that compared reboxetine with selective
serotonin reuptake inhibitors (SSRIs; fluoxetine, paroxetine, and citalopram). Empty boxes show published studies and filled
boxes show unpublished studies. Empty diamonds show subtotals (individual SSRIs) and filled diamonds show overall totals
(all SSRIs). CI, confidence interval; n, number of patients with event; N, number of patients in treatment group
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2=67.4%) was shown in
the meta-analysis of the rates of withdrawals owing to
adverse events in the comparison between reboxetine
andSSRIs,whichwasinpartowingtovariationsinthe
results of the individual SSRIs. The comparison
betweenreboxetineandfluoxetineshowedlowhetero-
geneity (I
2=19.3%) and statistically significantly more
withdrawals owing to adverse events for reboxetine
(OR 1.79, 95% CI 1.06 to 3.05; P=0.031). On the
other hand, the comparison between reboxetine and
paroxetine showed substantial heterogeneity
(I
2=84.2%), but the sensitivity analysis did not identify
a potential effect modifier. We therefore concluded
that there was no proof of a difference between rebox-
etine and paroxetine concerning rates of withdrawals
owing to adverse events. In the long term acute treat-
ment trial, reboxetine was inferior to citalopram (OR
4.61, 95% CI 2.15 to 9.89).
Further information on adverse events
The rates of serious adverse events (including events
related to suicide) were low and did not differ signifi-
cantly between reboxetine and placebo or reboxetine
and SSRIs (data on overall serious adverse events not
shown). A total of 18 serious adverse events related to
suicide (suicidal tendencies, suicide attempts, or com-
pletedsuicides)werenoted(sixforreboxetine;fourfor
placebo; eight for SSRIs). One death (a completed sui-
cide under placebo) was reported, which was the only
mortality in the study arms investigated. However,
with respect to study design and duration, none of the
trialswereaimedatinvestigatingsuiciderelatedevents
or overall mortality. The validity of the results of these
outcomes is therefore limited and the data do not pro-
vide clarification.
Publication bias
A substantial proportion of patient data (74%) had not
been previously published: 86% (1946/2256 patients)
inthecomparisonsofreboxetineandplaceboand67%
(1760/2641 patients) in the comparisonsof reboxetine
and SSRIs (table 1).
For both benefit outcomes, the addition of unpub-
lished data changed the superiority of reboxetine versus
placeboshowninpublisheddatatoanon-significantdif-
ference and also changed the non-significant difference
between reboxetine and SSRIs to an inferiority of rebo-
xetine(fig6).Comparisonofthepublisheddatawiththe
fulldataset(publishedandunpublished)showedthatthe
published data overestimated the beneficial effect of
reboxetine compared with placebo by 99-115% and of
reboxetine compared with SSRIs by 19-23%.
For both harm outcomes, the addition of unpub-
lished data changed the non-significant difference
between reboxetine and placebo shown in published
data to an inferiority of reboxetine. For rates of with-
drawals owing to adverse events, the addition of
unpublished data changed the non-significant differ-
ence between reboxetine and fluoxetine to an inferior-
ity of reboxetine; this was primarily owing to the
increased power of the analysis rather than to major
differences in withdrawal rates between published
and unpublished data. For patients with at least one
adverse event, no significant impact of unpublished
datawasshowninthecomparisonbetweenreboxetine
and SSRIs.
DISCUSSION
To our knowledge, this is the first systematic review of
a comprehensive evidence base of published and
unpublishedacutetreatmenttrialsofreboxetineversus
Patients with adverse events
  014
  091
  015
  046
  047
  050
  045
  049
Total
Total heterogeneity: I2=44.0%, P=0.085; total effect: P<0.001
Withdrawal owing to adverse events
  014
  091
  015
  046
  047
  050
  045
  049
Total
Total heterogeneity: I2=38.4%, P=0.124; total effect: P<0.001
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3.24 (1.60 to 6.57)
2.18 (1.14 to 4.18)
4.30 (1.85 to 9.99)
2.14 (1.59 to 2.88)
0.94 (0.43 to 2.04)
1.00 (0.06 to 16.82)
1.63 (0.61 to 4.38)
2.97 (1.36 to 6.48)
2.03 (0.93 to 4.44)
2.52 (1.23 to 5.20)
2.32 (0.89 to 6.00)
9.33 (2.71 to 32.16)
2.21 (1.45 to 3.37)
15.8
4.5
15.2
15.5
16.8
11.1
12.3
8.8
100.00
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2.1
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17.1
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8.7
100.00
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Odds ratio
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Weight
(%)
84/126
24/28
71/112
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138/150
68/89
98/106
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14/126
1/28
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27/150
15/89
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Reboxetine
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78/128
13/28
58/112
208/254
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117/150
52/87
77/104
804/1115
15/128
1/28
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9/254
10/252
12/150
7/87
3/104
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(n/N)
Fig 4 | Forest plot showing meta-analyses of rates of patients with at least one adverse event and rates of withdrawals owing
to adverse events for trials that compared reboxetine with placebo. Empty boxes show published studies and filled boxes
show unpublished studies. CI, confidence interval; n, number of patients with event; N, number of patients in treatment group
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order. We found that, overall, reboxetine was ineffec-
tive as an antidepressant because it showed no benefit
over placebo and was inferior to SSRIs for remission
and response rates. A benefit of reboxetine (higher
response rates) was shown in a placebo controlled
trial in inpatients; however, this trial was too small to
drawgeneralconclusionsontheeffectofreboxetinein
thispatientpopulation.Reboxetinewasinferiortopla-
cebo for both harm outcomes and to fluoxetine for
rates of withdrawals owing to adverse events.
Given the potential underdosing of fluoxetine and
citalopram in five trials, our findings on reboxetine
might be considered conservative. At the same time,
the advantages of SSRIs concerning harm might be
overestimated. However, as stated, no clear dose-
response relationship has been shown for fluoxetine
and citalopram.
2425 Furthermore, in our test of assay
sensitivity that included two of the four potentially
underdosedfluoxetinearms,eventhelowerfluoxetine
dose showed a clear benefit compared with placebo
(OR1.98,95%CI1.19to3.28,I
2=53.8%),thusqualify-
ing the effect of dosing in treatment for depression.
Data on 74% of the patients included in our analysis
was unpublished, indicating that the published evi-
dence on reboxetine so far has been severely affected
by publication bias. Our comparison of published and
unpublishedtrialsconfirmedthisassumption:theposi-
tive benefit-risk ratio of reboxetine in the published
literature was changed to a negative ratio if unpub-
lished trials were added to the analysis.
Comparison with other reviews
Theresultsofourreviewlargelycontradictthefindings
of previous systematic reviews and analyses of rebox-
etine versus placebo
679 and reboxetine versus active
comparators.
8911
The solely placebo controlled analyses by Ferguson
et al
6 and Montgomery et al
7 both found greater effi-
cacy (including higher response rates) for reboxetine
compared with placebo, and Ferguson et al also found
comparable harms. However, both reviews included
only threeofthe eightstudiesconsideredinourreview
(plus the inpatient trial by Ban et al 1998
26). These two
reviews also includedonlyoneunpublishedtrial(015),
even though the relevant unpublished trials had been
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Fig 5 | Forest plot showing meta-analyses of rates of patients with at least one adverse event and rates of withdrawals owing to
adverse events for trials that compared reboxetine with selective serotonin reuptake inhibitors (SSRIs; fluoxetine and
paroxetine). Empty boxes show published studies and filled boxes show unpublished studies. Empty diamonds show subtotals
(individual SSRIs) and filled diamonds show overall totals (all SSRIs). CI, confidence interval; n, number of patients with event;
N, number of patients in treatment group
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both reviews were cowritten by a sponsor employee.
The meta-analysis by Chuluunkhuu et al
9 concluded
that reboxetine showed superior efficacy to placebo
and found no difference in efficacy of reboxetine com-
paredwith SSRIsandotherantidepressants.However,
this analysis considered only published data.
Although the meta-analysis by Papakostas et al
8
identified and included a large body of unpublished
studies that used SSRIs as the control (the same set as
we used), they found no significant difference in
response rates between SSRIs and reboxetine (risk
ratio 1.08, 95% CI 0.98 to 1.19). Their analysis
included the long term acute treatment trial 043,
whichweanalysedseparately.Incontrast,ouranalysis
showed that reboxetine was inferior to SSRIs, even if
trial043wasincluded(recalculatedaccordingtoPapa-
kostas:riskratio(SSRIvreboxetine)1.10,95%CI1.03
to 1.17; P=0.003). The reason for this discrepancy is
unclear, because Papakostas et al reported only point
estimates and CIs and did not report the number of
actual events or the corresponding populations.
The widely discussed systematic review by Cipriani
et al,
11 which assessed 12 new generation anti-
depressants in a network meta-analysis and ranked
reboxetine last, had similar findings to those of our
review. These authors found significantly lower
response rates for reboxetine than for all SSRIs inves-
tigated, as well as significantly higher dropout rates
versus fluoxetine, citalopram, escitalopram, and ser-
traline. However, despite the similarity in findings,
theevidencebaseoftheCiprianireviewdifferedmark-
edly from that in our review because placebo con-
trolled trials were omitted and trials that were not
double blind, which carry a higher risk of bias, were
considered. In addition, unpublished trials of reboxe-
tine on file at the manufacturers were not considered,
even though significant publication bias has been
0.20
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Fig 6 | Forest plot showing meta-analyses of published, unpublished, and all trials. Publication bias (right column) is presented
as the ratio of odds ratios of published results versus overall results. The extent of publication bias is expressed as
percentage change between the analysis of published trials only and the analysis of all trials (that is, publication
bias=100×(ORpublished data/ORtotal data–1)). *Fluoxetine controlled studies only
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bias noted, the results of the Cipriani review should be
interpreted with caution.
Our findings that reboxetine was superior (higher
response rates) to placebo in a small trial in inpatients
and that patient setting was a probable effect modifier
are supported by the four week active controlled and
placebo controlled inpatient trial by Ban et al
26 (n=169
in the reboxetine and placebo arms), which we
excluded owing to its short duration. Ban et al also
found a statistically significant higher response rate in
inpatients who received reboxetine compared with
those who received placebo (60% v 35%; OR 2.70,
95% CI 1.45 to 5.03 (own calculation)).
Strengths and limitations of the review
The main strength of our review is the inclusion of a
large amount of previously unpublished data. As we
made extensive efforts to identify unpublished trials,
we are optimistic that we analysed the vast majority
or even all of the placebo controlled and SSRI con-
trolled double blind randomised trials of reboxetine
in adults with major depression.
Our review also has a number of limitations. We
only had access to aggregated data. To assess the
impact of effect modifiers, meta-analysis of individual
patient data would be needed to determine the setting
instudieswithmixedsettingsandtotestourhypothesis
that the setting was the effect modifier explaining the
substantial heterogeneity in the meta-analysis of
response rates in placebo controlled trials.
Our results are further limited by the fact that they
only refer to acute treatment trials, only one of which
lasted more than eight weeks. However, six to eight
weeksisthestandardstudydurationintrialsinvestigat-
ing the acute treatment of depression. The long term
acute treatment trial showed similar, though not
always statistically significant, trends to the short term
trials.Otherlongtermoutcomesindepression,suchas
preventionofrelapseorrecurrence,werenotthefocus
of this paper.
Finally,exceptforasubgroupanalysisforgenderand
setting, we assessed total populations of patients with
majordepressivedisorder.Noanalyseswereperformed
in other subgroups of patients (for example, patients
with severe disease or specific major depressive
Table 4 |Examples of publication bias and industry sponsorship bias in trials of antidepressants
Source Study type Antidepressant type Findings
Turner et al 2008
33 Comparison of FDA reviews
and matching publications
SSRIs, SNRIs, NDRIs, TeCAs,
and atypical
antidepressants
“Among 74 FDA registered studies, 31%, accounting for 3449 study participants, were notpublished .
..Atotalof37studiesviewedbytheFDAashavingpositiveresultswerepublished. ..Studiesviewed
by the FDA as having negative or questionable results were, with 3 exceptions, either not published
(22 studies) or published in a way that, in our opinion, conveyed a positive outcome (11 studies).
According to the published literature, it appeared that 94% of the trials conducted were positive. By
contrast, the FDA analysis showed that 51% were positive . . . the increase in effect size ranged from
11% to 69% for individual drugs and was 32% overall.”
Kirsch et al 2008
63 Meta-analysis of data
submitted to the FDA
SSRIs, SNRIs, and atypical
antidepressants
“[T]he FDA public disclosure did not include mean changes for nine trials that were deemed adequate
and wellcontrolledbut thatfailed toachievea statistically significantbenefitfor drugoverplacebo. ..
Specifically, four sertraline trials involving 486 participants and one citalopram trial involving 274
participants were reported as having failed to achieve a statistically significant drug effect, without
reporting mean Hamilton rating scale of depression scores. We were unable to find data from these
trials on pharmaceutical company websites or through our search of the published literature. These
omissions represent 38% of patients in sertraline trials and 23% of patients in citalopram trials.”
Whittingtonetal2004
34 Systematic review of
published versus
unpublished data
SSRIs, SNRIs “Data for two published trials suggest that fluoxetine has a favourable risk-benefit profile, and
unpublished data lend support to this finding. Published results from one trial of paroxetine and two
trials of sertraline suggest equivocal or weak positive risk-benefit profiles. However, in both cases,
addition of unpublished data indicates that risks outweigh benefits. Data from unpublished trials of
citalopram and venlafaxine show unfavourable risk-benefit profiles.”
Melander et al 2003
38 Analysis of industry
sponsored studies in new
drug applications
SSRIs “Multiple publication: 21 studies contributed to at least two publications each, and three studies
contributed to five publications. Selective publication: studies showing significant effects of drug
were published as stand alone publications more often than studies with non-significant results.
Selective reporting: many publications ignored the results of intention to treat analyses and reported
the more favourable per protocol analyses only.”
Jureidini et al 2008
64 Case report on selective
reporting
Paroxetine “Thepublishedreportofstudy 329 ofparoxetineinadolescents sponsoredbyGlaxoSmithKline claims
that ‘paroxetine is generally well tolerated and effective for major depression in adolescents.’ By
contrast, documents obtained during litigation reveal that study 329 was negative for efficacy on all
eight protocol specified outcomes and positive for harm.”
Tungaraza et al 2007
65 Analysis of influence of
industry authorship and
funding
Not specified* “Independent studies were more likely to report negative findings than were industry funded studies.
However, the involvement of a drug company employee had a much greater effect on study outcome
than financial sponsorship alone.”
Perlis et al 2005
66 Analysis of influence of
industry funding and
financial conflict of interest
Not specified* “Among the 162 randomised, double blind, placebo controlled studies examined, those that reported
conflictofinterestwere4.9 timesmorelikelytoreportpositiveresults;thisassociationwassignificant
only among the subset of pharmaceutical industry funded studies.”
Kelly et al 2006
67 Analysis of influence of
industry funding
Not specified* “Favourable outcomes were significantly more common in studies sponsored by the drug
manufacturer (78%)thaninstudies withoutindustrysponsorship(48%)orsponsored bya competitor
(28%).”
*Findings also refer to other psychiatric drugs. All analyses examined drug trials reported in psychiatric journals. No separate results for antidepressants were reported.
FDA, Food and Drug Administration; NDA, new drug application; NDRI, norepinephrine and dopamine reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; SSRI,
selective serotonin reuptake inhibitor; TeCA, tetracyclic antidepressant.
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ment), in which treatment effects may differ.
Publication bias
Ourdifficultiesinretrievingunpublishedtrialdataand
our results of the comparison between published and
previously unpublished trials are a further example of
publication bias, a problem that has been known in
clinical research for decades.
27-31 A recent narrative
review has shown that publication bias affects a wide
range of medical indications and interventions.
32 Such
bias, including industry sponsorship bias, has fre-
quently been identified in research on antidepressants
(table 4).Forexample,Turneretal
33publishedacom-
parison of FDA reviews of placebo controlled anti-
depressant trials and matching publications, which
showed that, overall, published trials overestimated
effect sizes by 32% (11 to 69% for individual agents);
the estimates in our review were even higher. Whit-
tington et al
34 investigated SSRIs in the treatment of
childhood depression and found that the addition of
unpublished data reversed the benefit-risk profile for
all but one SSRI.
In addition to publication bias, outcome reporting
bias has been identified as a major problem in the
reporting of clinical trials, resulting in a distorted pub-
lic record of an intervention.
35-38 Our review also iden-
tifiedthistypeofbias—forthreereboxetinetrials,only
results on subpopulations or selected outcomes were
available in the published literature (trials 047, 050,
052; table 1).
The more positive benefit-risk ratio in published
data compared with unpublished data also affects the
content of clinical guidelines. For example, the
National Institute for Health and Clinical Excellence
(NICE)guidelineonthetreatmentandmanagementof
depression in adults is based on published studies of
reboxetine, and concludes that “Reboxetine is super-
ior to placebo and as effective as other antidepressants
in the treatment of depression.”
10 In our opinion, this
conclusion can no longer be upheld.
Theongoingproblem ofpublicationbias showsthat
unbiaseddecisionmakinginhealthcarerequiresman-
datory public disclosure of all clinical trial data. The
US FDA Amendments Act of 2007
39 solves the pro-
blem in part by requiring protocol information and
study results for clinical trials to be made public on
the clinicaltrials.gov website (www.clinicaltrials.gov;
please see accompanying comment (doi:10.1136/
bmj.c4942) for further details). Similar legislation is
also being introduced in Europe, with the mandatory
public disclosure of data from the clinical trials data-
base EudraCT (eudract.ema.europa.eu),
4041 but the
date of implementation is not yet clear.
As the full assessment reports on reboxetine pre-
pared by regulatory authorities are not publicly avail-
able, it is not clear as to how the comprehensive body
of evidence (including that on efficacy outcomes) gen-
erated after reboxetine was approved in Europe in the
late 1990s has been analysed by these authorities. The
reason for the difference in approval status of reboxe-
tinebetweenEuropeandthe USthusremainsunclear.
Conclusions and policy implications
Ouranalysisofacomprehensiveevidencebaseofpub-
lished and unpublished trials of reboxetine compared
with placebo or SSRIs in adults with major depressive
disorder indicates that reboxetine is, overall, an inef-
fective and potentially harmful antidepressant. Pub-
lished evidence on reboxetine has been substantially
affected by publication bias, underlining the urgent
need for mandatory publication of clinical trial data,
including data on older agents.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Reboxetine has been approved for the treatment of major depression in many European
countries, but the application for approval was rejected in the United States
Doubts have been raised about the efficacy of reboxetine
Research into antidepressants is particularly affected by publication bias
WHAT THIS STUDY ADDS
Overall, reboxetine is not effective for the treatment of major depressive disorder
We found a higher rate of patients affected by adverse events than with placebo and higher
withdrawal rates owing to adverse events than with placebo and fluoxetine
This meta-analysis provides a striking example of publication bias, in which the previously
favourable risk-benefit profile of reboxetine shown in published trials is reversed by the
addition of unpublished data
Post-approval regulatory decisions (for example, reimbursement decisions based on the
findings of health technology assessment reports) might be affected by publication bias
Our findings underline the need for mandatory publication of clinical trial results
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